Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation

NCT02812290 · View on ClinicalTrials.gov ↗

Study Summary

Objective: To evaluate the potential impact of molecular phenotyping of transbronchial biopsies in lung transplant recipients with allograft dysfunction, and the potential for developing a safer endobronchial mucosal biopsy format.

Conditions Studied

Interventions

  • PROCEDURE Lung transplant biopsy bites.

Study Locations (11)

Other

  • The Alfred Hospital, Monash University — Melbourne
  • Department of Thoracic Surgery, Medical University of Vienna — Vienna
  • Charles University/Hospital Motol — Prague
  • Thoracic Surgery Transplant Clinic — Szczecin

Alberta

  • Alberta Transplant Applied Genomics Centre, University of Alberta — Edmonton
  • Department of Medicine, University of Alberta — Edmonton

Arizona

  • St. Joseph's Hospital and Medical Center 350 West Thomas Road, Floor 8HLT — Phoenix

Maryland

  • University of Maryland School of Medicine — Baltimore

Missouri

  • Division of Pulmonary and Critical Care, Washington University School of Medicine — St Louis

Texas

  • University of Texas at San Antonio — San Antonio

Ontario

  • University Health Network, Toronto General Hospital — Toronto

Trial Details

FieldValue
Enrollment Target 700 participants
Start Date 2016-05
Est. Completion 2026-12

Sponsor

University of Alberta

135 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02812290

The ClinicalTrials.gov registry entry for NCT02812290 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alberta, which has 135 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Lung Transplant Rejection appearing as the primary indexed condition, and to 1 intervention — of which Lung transplant biopsy bites. is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02812290 reports 11 study locations spanning 7 distinct geographic areas — top geographies include Other, Alberta, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02812290 about?

NCT02812290 is a clinical study titled "Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation". Objective: To evaluate the potential impact of molecular phenotyping of transbronchial biopsies in lung transplant recipients with allograft dysfunction, and the potential for developing a safer endobronchial mucosal biopsy format.

What is the current status of trial NCT02812290?

This trial is currently recruiting. The enrollment target is 700 participants. The study started on 2016-05. Estimated completion is 2026-12.

What conditions does trial NCT02812290 study?

This clinical trial studies the following conditions: Lung Transplant Rejection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02812290?

The interventions under investigation include: Lung transplant biopsy bites. (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02812290?

This trial is sponsored by University of Alberta, which has 135 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02812290 being conducted?

This trial has 11 study locations across Arizona, Maryland, Missouri, Texas, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial